Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Disease 2Neoplasms, Plasma Cell 1Lymphoma 1Alzheimer Disease 1

Interventions

Dexamethasone 17Bortezomib 11pomalidomide 10carfilzomib 6Lenalidomide 4imetelstat 3fludarabine 3daratumumab 3Standard of Care 3Panobinostat 3venetoclax 2siltuximab 2elotuzumab 2Cyclophosphamide 2Arsenic Trioxide 2spartalizumab 1shark cartilage extract 1selinexor 1saracatinib 1ricolinostat 1resiquimod 1poly ICLC 1plitidepsin 1pembrolizumab 1pazopanib 1motexafin gadolinium 1marizomib 1liposomal doxorubicin 1lestaurtinib 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × Positron-Emission Tomography × Clear all
NCT03371420 2023-04-18

PET Imaging of Subjects Using 124I-PU-AD

Samus Therapeutics, Inc.

Phase EARLY_PHASE1 Terminated
5 enrolled
LymphoidPlasma cell

Alzheimer Disease, Lymphoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡